| Literature DB >> 32038098 |
Vito Crincoli1, Maria Grazia Piancino2, Florenzo Iannone3, Mariella Errede1, Mariasevera Di Comite1.
Abstract
Aims: Systemic Lupus Erythematosus (SLE) is a connective tissue disease characterized by a wide range of pleomorphic pictures, including mucocutaneous, renal, musculoskeletal and neurological symptoms. It involves oral tissues, with hyposalivation, tooth decay, gingivitis, angular cheilitis, ulcers and glossitis. Temporomandibular disorders represent a heterogeneous group of inflammatory or degenerative diseases of the stomatognatic system, with algic and/or dysfunctional clinical features involving temporomandibular joint (TMJ) and related masticatory muscles. The aim of this study was to investigate the prevalence of oral manifestations and temporomandibular disorders (TMD) in SLE patients (Lp) compared with a control group.Entities:
Keywords: RDC/TMD; Systemic Lupus Erythematosus; oral features; temporomandibular disorders
Year: 2020 PMID: 32038098 PMCID: PMC6990878 DOI: 10.7150/ijms.38914
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Sociodemographic characteristics of Lupus patients (Lp) and controls.
| Sociodemographic characteristics | Lp | Controls | Test | |
|---|---|---|---|---|
| 44,44±15,04 | 46±13,49 | |||
| Male | 9 (16,4%) | 9 (16,4%) | ||
| Female | 46 (83,6%) | 46 (83,6%) | ||
| χ2=9,4184 | 0,0242 | |||
| Primary | 8 (14,5%) | 5 (9,1%) | ||
| Secondary | 17 (30,9%) | 7 (12,7%) | ||
| High | 25 (45,5%) | 29 (52,7%) | ||
| Academic | 5 (9,1%) | 14 (25,5%) | ||
| χ2=21,6894 | 0,0014 | |||
| Housewife | 18 (32,7%) | 13 (23,6%) | ||
| Retired | 5 (9,1%) | 5 (9,1%) | ||
| Office Worker | 12 (21,8%) | 11 (20%) | ||
| Self Employed | 3 (5,5%) | 4 (7,3%) | ||
| Not Employed | 12 (21,8%) | 1 (1,8%) | ||
| Public Employee | 2 (3,6%) | 16 (29,1%) | ||
| χ2=7,2039 | 0,0657 | |||
| Married | 29 (52,7%) | 39 (70,9%) | ||
| Widower | 1 (1,8%) | 2 (3,6%) | ||
| Single | 21 (38,2%) | 14 (25,5%) | ||
| Divorced | 4 (7,3%) | 0 | ||
Comorbidity in Lp and controls.
| Concomitant diseases | Lp, | Controls | Test | |
|---|---|---|---|---|
| Cardiopathy | 9 (16,4%) | 2 (3,6%) | χ2= 4,9045 | 0,027 |
| Diabetes mellitus | 2 (3,6%) | 0 | Fisher exact test | 0,248 |
| Esophageal disease | 8 (14,5%) | 3 (5,5%) | χ2= 2,5253 | 0,112 |
| Gastritis | 2 (3,6%) | 0 | Fisher exact test | 0,248 |
| Hypertension | 12 (21,8%) | 6 (10,9%) | χ2= 2,3913 | 0,122 |
| Hypovitaminosis D | 6 (10,9%) | 0 | Fisher exact test | 0,016 |
| Lung disease | 14 (25,5%) | 0 | χ2= 13,8318 | <0,001 |
| Osteoporosis | 10 (18,2%) | 1 (1,8%) | χ2= 6,4646 | 0,011 |
| Presence of removable prosthesis | 4 (7,3%) | 6 (10,9%) | χ2= 0,4400 | 0,507 |
| Raynaud syndrome | 10 (18,2%) | 0 | χ2= 8,9100 | 0,003 |
| Thyroid disease | 12 (21,8%) | 5 (9,1%) | Mid-p-test | 0,036 |
| Renal disease | 26 (47,3%) | 0 | χ2= 31,4789 | <0,001 |
| Blood disease | 24 (43,6%) | 0 | χ2= 28,1928 | <0,001 |
| Neurological disease | 7 (12,7%) | 0 | Fisher exact test | 0,006 |
Lp and controls' drugs.
| Drugs | Lp, | Controls | Test | |
|---|---|---|---|---|
| Azathioprine | 8 (14,5%) | 0 | Fisher exact test | 0,003 |
| Belimumab | 2 (3,6%) | 0 | Fisher exact test | 0,248 |
| Cyclophosphamide | 3 (5,5%) | 0 | Fisher exact test | 0,122 |
| Cyclosporine | 6 (10,9%) | 0 | Fisher exact test | 0,0135 |
| Corticosteroids | 41 (74,5%) | 0 | Fisher exact test | <0,001 |
| Hydroxychloroquine | 31 (56,4%) | 0 | Fisher exact test | <0,001 |
| Leflunomide | 1 (1,8%) | 0 | Fisher exact test | 0,500 |
| Methotrexate | 4 (7,3%) | 0 | Fisher exact test | 0,059 |
| Mycophenolate Mofetil | 15 (27,3%) | 0 | Fisher exact test | <0,001 |
| Rituximab | 2 (3,6%) | 0 | Fisher exact test | 0,248 |
Subjective complaints of oral discomfort in Lp and controls.
| Oral symptoms | Lp, | Controls, | χ2 | |
|---|---|---|---|---|
| Xerostomia | 17 (30,9%) | 8 (14,5%) | 4,1548 | 0,0415 |
| Dysgeusia | 5 (9,1%) | 2 (3,6%) | 1,3731 | 0,241 |
| Stomatodynia | 4 (7,3%) | 3 (5,5%) | 0,1526 | 0,696 |
TMD symptoms in Lp and controls.
| TMDs | Lp, | Controls, | Test | |
|---|---|---|---|---|
| Arthralgia | 17 (30,9%) | 10 (18,2%) | χ2= 2,4052 | 0,121 |
| Temple headache | 29 (52,7%) | 18 (32,7%) | χ2= 4,4542 | 0,035 |
| Sensation of stuck jaw | 13 (23,6%) | 6 (10,9%) | Mid-p-test | 0,043 |
| Masticatory muscle pain during function | 14 (25,5%) | 8 (14,5%) | χ2= 2,0455 | 0,153 |
| Neck and shoulder muscles pain | 38 (69,1%) | 35 (63,6%) | χ2= 0,3665 | 0,545 |
| tinnitus | 16 (29,1%) | 10 (18,1%) | χ2= 1,8132 | 0,178 |
Myofascial pain in Lp and controls.
| Muscle | Lp, | Controls, | Test | |
|---|---|---|---|---|
| Anterior temporalis muscles | 21 (38,2%) | 17 (30,9%) | χ2= 0,6433 | 0,423 |
| Medial temporalis muscles | 16 (29,1%) | 12 (21,8%) | χ2= 0,7666 | 0,381 |
| Posterior temporalis muscles | 11 (20,0%) | 10 (18,2%) | χ2= 0,0589 | 0,808 |
| Superficial masseter muscles | 29 (52,7%) | 25 (45,5%) | χ2= 0,5820 | 0,446 |
| Deep masseter muscles | 29 (52,7%) | 26 (47,3%) | χ2= 0,3273 | 0,567 |
| medial pterygoid muscles | 29 (52,7%) | 30 (54,5%) | χ2= 0,0366 | 0,848 |
| lateral pterygoid muscle | 30 (54,5%) | 37 (67,3%) | χ2= 1,8709 | 0,171 |
| digastric muscle - anterior belly | 10 (18,2%) | 11 (20,0%) | χ2= 1,0589 | 0,808 |
| digastric muscle - posterior belly | 13 (23,6%) | 18 (14,5%) | χ2= 1,4714 | 0,225 |
| Mylohyoid muscles | 14 (25,5%) | 11 (20,0%) | χ2= 0,4659 | 0,495 |
Oral signs for Lp and controls.
| Oral signs | Lp, | Controls, | Test | |
|---|---|---|---|---|
| Candidiasis | 1 (1,8%) | 0 | Fisher exact test | 0,500 |
| Cheilitis | 5 (9,1%) | 0 | Fisher exact test | 0,0284 |
| Erythema | 3 (5,5%) | 0 | Fisher exact test | 0,122 |
| Petechiae | 3 (5,5%) | 0 | Fisher exact test | 0,122 |
| Fissured tongue | 7 (12,7%) | 0 | Fisher exact test | 0,006 |
| Oral ulcers | 11 (20%) | 3 (5,5%) | χ2= 4,0104 | 0,045 |
| Erythematous and hyperkeratotic areas | 2 (3,6%) | 0 | Fisher exact test | 0,248 |
| Others | 4 (7,3%) | 12 (21,8%) | χ2= 4,6383 | 0,031 |
Figure 1Mean values ± SD of Lp and control group. Lp patients show a reduced salivary flow.
Restricted Movements (RM).
| Measurements (mm); | Lp | Controls | T Student | |
|---|---|---|---|---|
| Opening | 45,20 ±8,61 | 44,24 ± 7,65 | 0,6228 | 0,5347 |
| Laterotrusion right | 5,85 ± 3,49 | 6,86 ± 2,5 | 1,681 | 0,0957 |
| Laterotrusion left | 6,13 ± 4,02 | 7,636 ±2,98 | 2,225 | 0,0282 |
| Protrusion | 4,09 ± 2,36 | 6,091 ± 2,75 | 4,069 | < 0,0001 |
Parafunctional signs.
| Parafunctional signs | Lp | Controls | Test | |
|---|---|---|---|---|
| Wear facets | 32 (58,2%) | 25 (45,5%) | χ2= 1,7842 | 0,550 |
| Oral frictional hyperkeratosis | 26 (47,3%) | 19 (34,5%) | χ2=1,8427 | 0,175 |
| Indentations on lateral edges of tongue | 40 (72,7%) | 25 (45,5%) | χ2=7,3709 | 0,007 |